中华肾脏病杂志
中華腎髒病雜誌
중화신장병잡지
2014年
9期
671-678
,共8页
罗富里%蔡得汉%杨林%李赟
囉富裏%蔡得漢%楊林%李赟
라부리%채득한%양림%리빈
Meta分析%腹膜透析%透析液%治疗结果%葡萄糖降解产物
Meta分析%腹膜透析%透析液%治療結果%葡萄糖降解產物
Meta분석%복막투석%투석액%치료결과%포도당강해산물
Meta-analysis%Peritoneal dialysis%Dialysis solutions%Treatment outcome%Glucose degradation products
目的 系统评价低葡萄糖降解产物的双室双袋腹透液(PDF)在腹膜透析(PD)患者中的应用效果.方法 检索Pubmed、EBMASE、Cochrane Library、万方、维普、CNKI、CBM等数据库,并手工检索相关文献,检索年限从建库至2013年12月,检索关于低葡萄糖降解产物的双室双袋PDF与传统PDF的随机对照试验,使用RevMan 5.2对入选试验进行Meta分析.结果 共纳入12篇文献,11项研究,1 059例患者.Meta分析结果显示:(1)低葡萄糖降解产物PDF组患者透出液CA125水平、残余肾功能高于传统PDF组(WMD=19.61,95％CI 12.04～ 27.18,P＜ 0.01:WMD=0.78,95％CI 0.14 ～ 1.43,P=0.02),差异均有统计学意义;(2)两组患者24 h超滤量、血浆HCO3-、腹膜炎发生率差异均无统计学意义(均P＞0.05);(3)4项研究报道低葡萄糖降解产物PDF组与传统PDF组PD技术生存时间差异无统计学意义(P＞0.05).结论 低葡萄糖降解产物的双室双袋PDF安全、有效,在改善患者腹膜超滤及酸中毒方面没有特殊优势,不能减少腹膜炎的发生,但这种PDF可以保护腹膜间皮细胞功能,改善PD患者残余肾功能,且不影响患者PD技术生存时间.
目的 繫統評價低葡萄糖降解產物的雙室雙袋腹透液(PDF)在腹膜透析(PD)患者中的應用效果.方法 檢索Pubmed、EBMASE、Cochrane Library、萬方、維普、CNKI、CBM等數據庫,併手工檢索相關文獻,檢索年限從建庫至2013年12月,檢索關于低葡萄糖降解產物的雙室雙袋PDF與傳統PDF的隨機對照試驗,使用RevMan 5.2對入選試驗進行Meta分析.結果 共納入12篇文獻,11項研究,1 059例患者.Meta分析結果顯示:(1)低葡萄糖降解產物PDF組患者透齣液CA125水平、殘餘腎功能高于傳統PDF組(WMD=19.61,95％CI 12.04～ 27.18,P＜ 0.01:WMD=0.78,95％CI 0.14 ～ 1.43,P=0.02),差異均有統計學意義;(2)兩組患者24 h超濾量、血漿HCO3-、腹膜炎髮生率差異均無統計學意義(均P＞0.05);(3)4項研究報道低葡萄糖降解產物PDF組與傳統PDF組PD技術生存時間差異無統計學意義(P＞0.05).結論 低葡萄糖降解產物的雙室雙袋PDF安全、有效,在改善患者腹膜超濾及痠中毒方麵沒有特殊優勢,不能減少腹膜炎的髮生,但這種PDF可以保護腹膜間皮細胞功能,改善PD患者殘餘腎功能,且不影響患者PD技術生存時間.
목적 계통평개저포도당강해산물적쌍실쌍대복투액(PDF)재복막투석(PD)환자중적응용효과.방법 검색Pubmed、EBMASE、Cochrane Library、만방、유보、CNKI、CBM등수거고,병수공검색상관문헌,검색년한종건고지2013년12월,검색관우저포도당강해산물적쌍실쌍대PDF여전통PDF적수궤대조시험,사용RevMan 5.2대입선시험진행Meta분석.결과 공납입12편문헌,11항연구,1 059례환자.Meta분석결과현시:(1)저포도당강해산물PDF조환자투출액CA125수평、잔여신공능고우전통PDF조(WMD=19.61,95％CI 12.04～ 27.18,P＜ 0.01:WMD=0.78,95％CI 0.14 ～ 1.43,P=0.02),차이균유통계학의의;(2)량조환자24 h초려량、혈장HCO3-、복막염발생솔차이균무통계학의의(균P＞0.05);(3)4항연구보도저포도당강해산물PDF조여전통PDF조PD기술생존시간차이무통계학의의(P＞0.05).결론 저포도당강해산물적쌍실쌍대PDF안전、유효,재개선환자복막초려급산중독방면몰유특수우세,불능감소복막염적발생,단저충PDF가이보호복막간피세포공능,개선PD환자잔여신공능,차불영향환자PD기술생존시간.
Objectives To study the efficacy of the two-compartment peritoneal dialysis fluid with low glucose degradation products in peritoneal dialysis (PD) patients.Methods Pubmed,EBMASE,Cochrane Library,Wanfang,VIP,CNKI,CBM and other databases were searched,at the same time the information form relevant literatures until December 2013 were searched by hand.To be eligible,studies had to be randomized controlled trials that allocated PD patients to two-compartment peritoneal dialysis fluid with low glucose degradation products (low-GPDs group) or to traditional dialysis fluid (control group).The qualities of included articles were assessed and then a meta-analysis was conducted by using RevMan 5.2 software.Results A total of 12 documents,11 studies met the inclusion criteria,and 1 059 cases were included.Meta-analysis results were as follows:(1)the low-GPDs group had higher level of CA125 in peritoneal dialysis effluent,higher residual renal function compared with that in the control group and the weighted mean difference were 19.61 (95％CI 12.04-27.18,P ＜ 0.01) and 0.78 (0.14-1.43,P=0.02),respectively; (2)There was no statistically significant difference between control and low-GPDs group in the ultrafiltration,peritonitis and plasma bicarbonate (all P ＞ 0.05); (3)Four studies showed no difference in peritoneal dialysis technique survival between the two group (P ＞ 0.05).Conclusions The two-compartment peritoneal dialysis fluid with low glucose degradation products is effective and safe,has no negative effects on the frequency of peritonitis,patient' s peritoneal member transport function and plasma bicarbonate,but it causes less mesothelial damage and has higher residual renal function in patients than conventional ones,and does not affect the technique survival time.
